Form 4: Avidity Biosciences' Chief Program Officer Exercises Options and Sells Shares
SEC Form 4
Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 1, 2025, Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, exercised stock options to acquire 5,546 shares at $14.70 and 329 shares at $16.65.
- Simultaneously, Gallagher sold 5,546 shares and 329 shares at a weighted-average price of $27.8274, with individual sales ranging from $26.67 to $29.16.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2024.
- Following these transactions, Gallagher directly owns 50,554 shares of Avidity Biosciences common stock and holds options to purchase 13,829 shares at $14.70 and 34,346 shares at $16.65.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is a standard practice in the biotech industry.
Comparison to Industry Standards
- Insider transactions are common in publicly traded companies, especially in the biotech sector where stock options are a significant part of executive compensation.
- The use of Rule 10b5-1 trading plans is a standard practice to allow insiders to sell shares without being accused of trading on non-public information.
- Comparable companies such as Ionis Pharmaceuticals and Alnylam Pharmaceuticals also see regular Form 4 filings from their executives.
Stakeholder Impact
- Shareholders are informed about the trading activity of a key executive.
- The transactions may have a minor impact on the stock price due to the volume of shares traded.
Key Dates
| Date | Description |
|---|---|
| June 12, 2024 | Date the Reporting Person adopted the Rule 10b5-1 trading plan. |
| January 20, 2022 | Date of grant for stock options that vest monthly until January 20, 2026. |
| July 18, 2022 | Date of grant for stock options that vest monthly until July 18, 2026. |
| April 01, 2025 | Date of stock option exercise and share sale. |
| April 03, 2025 | Date of Form 4 filing. |
| January 19, 2032 | Expiration date of some stock options. |
| July 17, 2032 | Expiration date of some stock options. |
Keywords
Avidity Biosciences, Kathleen P. Gallagher, stock options, share sale, Form 4, Rule 10b5-1, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.